Trial Profile

POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant; Tamoxifen
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Pharmacodynamics; Therapeutic Use
Acronyms POLARIS
Sponsors Pfizer

04 Jun 2024 Results(N=1250) describing Real-world progression-free survival (rwPFS) and overall survival (OS) ,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Results assessing real-world impact on outcomes in patients advanced breast cancer, presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Results assessing impact of comorbidities on pt quality of life (QoL) using the EORTC-QLQ-C30 questionnaire. presented at the 48th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com